ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 153 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2017. The put-call ratio across all filers is 2.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $6,632,000 | -48.9% | 169,239 | -5.7% | 0.17% | -47.6% |
| Q1 2018 | $12,981,000 | -23.0% | 179,463 | -29.9% | 0.32% | -19.9% |
| Q4 2017 | $16,861,000 | +16.0% | 256,092 | -11.7% | 0.40% | +13.5% |
| Q3 2017 | $14,536,000 | -1.4% | 290,027 | -9.0% | 0.35% | -5.2% |
| Q2 2017 | $14,748,000 | – | 318,667 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |